Abstract
A series of substituted pyridinylpyrazole (or isoxazole) derivatives were synthesized and evaluated for their anti-inflammatory (AI) activity using formalin-induced paw edema bioassays. Their inhibitory activities of cyclooxygenase-1 and cyclooxygenase-2 (COX-1 and COX-2) were also determined. The analgesic activity of the same compounds was evaluated using rat-tail withdrawal technique. Their antipyretic activity was also evaluated. The results revealed that compounds 4a,b, 6a, 8a, 14c and 15a exhibited significant AI and analgesic activities. Compounds 5a, 6a and 8a displayed good antipyretic activity. Compounds 14c and 15a showed good COX-2 inhibitory activity and weak inhibition of COX-1. Additionally, the most active compounds were shown to have a large safety margin (ALD50 >300-400 mg / Kg) and minimal ulcerogenic potentialities when administered orally at a dose of 300 mg/Kg. Docking studies for 14c and 15a with COX-2 showed good binding profile. Antimicrobial evaluation proved that most of the compounds exhibited distinctive activity against the gram negative bacteria, P. aeruginosa and E coli.
Keywords: Pyridinylpyrazoles, pyridinylisoxazoles, anti-inflammatory activity, analgesic activity, antipyretic activity, antimicrobial activity.
Medicinal Chemistry
Title:Design, Synthesis and Biological Screening of Some Pyridinylpyrazole and Pyridinylisoxazole Derivatives as Potential Anti-inflammatory, Analgesic, Antipyretic and Antimicrobial Agents
Volume: 10 Issue: 3
Author(s): Soad A.M. El-Hawash, Raafat Soliman, Amal M. Youssef, Hanan M.A. Ragab, Perihan A.S. Elzahhar, Ibrahim M. El-Ashmawey, Abeer E. Abdel Wahab and Iman A. Shaat
Affiliation:
Keywords: Pyridinylpyrazoles, pyridinylisoxazoles, anti-inflammatory activity, analgesic activity, antipyretic activity, antimicrobial activity.
Abstract: A series of substituted pyridinylpyrazole (or isoxazole) derivatives were synthesized and evaluated for their anti-inflammatory (AI) activity using formalin-induced paw edema bioassays. Their inhibitory activities of cyclooxygenase-1 and cyclooxygenase-2 (COX-1 and COX-2) were also determined. The analgesic activity of the same compounds was evaluated using rat-tail withdrawal technique. Their antipyretic activity was also evaluated. The results revealed that compounds 4a,b, 6a, 8a, 14c and 15a exhibited significant AI and analgesic activities. Compounds 5a, 6a and 8a displayed good antipyretic activity. Compounds 14c and 15a showed good COX-2 inhibitory activity and weak inhibition of COX-1. Additionally, the most active compounds were shown to have a large safety margin (ALD50 >300-400 mg / Kg) and minimal ulcerogenic potentialities when administered orally at a dose of 300 mg/Kg. Docking studies for 14c and 15a with COX-2 showed good binding profile. Antimicrobial evaluation proved that most of the compounds exhibited distinctive activity against the gram negative bacteria, P. aeruginosa and E coli.
Export Options
About this article
Cite this article as:
El-Hawash A.M. Soad, Soliman Raafat, Youssef M. Amal, Ragab M.A. Hanan, Elzahhar A.S. Perihan, El-Ashmawey M. Ibrahim, Abdel Wahab E. Abeer and Shaat A. Iman, Design, Synthesis and Biological Screening of Some Pyridinylpyrazole and Pyridinylisoxazole Derivatives as Potential Anti-inflammatory, Analgesic, Antipyretic and Antimicrobial Agents, Medicinal Chemistry 2014; 10 (3) . https://dx.doi.org/10.2174/15734064113096660044
DOI https://dx.doi.org/10.2174/15734064113096660044 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Optical Imaging of Microvascular Morphology and Perfusion
Current Angiogenesis (Discontinued) Passive Smoking and Coronary Heart Disease
Current Vascular Pharmacology Hypersensitivity Reactions to Ophthalmic Products
Current Pharmaceutical Design Vasospastic Angina and Ca Channel Blockers
Current Hypertension Reviews Recent Patents and Emerging Therapeutics in the Treatment of Allergic Conjunctivitis
Recent Patents on Inflammation & Allergy Drug Discovery Therapeutic Effects and Mechanisms of Action of Cyclosporine A Ophthalmic Solution in the Treatment of Vernal Keratoconjunctivitis
Current Pharmaceutical Analysis Can Imaging Techniques Identify Smoking-Related Cardiovascular Disease?
Current Pharmaceutical Design Role of Diagnostic Ultrasound in Patient Selection for Stroke Intervention
Recent Patents on CNS Drug Discovery (Discontinued) Restoring the Dysfunctional Endothelium
Current Pharmaceutical Design Aldose Reductase, Still a Compelling Target for Diabetic Neuropathy
Current Drug Targets Melatonin as a Therapeutic Resource for Inflammatory Visual Diseases
Current Neuropharmacology Collateral Circulation in Chronic Total Occlusions – an interventional perspective
Current Cardiology Reviews Vasopressin in Liver Disease – Should We Turn On or Off?
Current Clinical Pharmacology The Effect of Serotonin 5-HT2 Receptor Inhibitor on Vasomotor Responses
Vascular Disease Prevention (Discontinued) Micro- and Macrovascular Treatment Targets in Scleroderma Heart Disease
Current Pharmaceutical Design Olive Oil and Haemostasis: Platelet Function, Thrombogenesis and Fibrinolysis
Current Pharmaceutical Design Cerebroprotective Functions of HO-2
Current Pharmaceutical Design TRH/TRH-R1 Receptor Signaling in the Brain Medulla as a Pathway of Vagally Mediated Gut Responses During the Cephalic Phase
Current Pharmaceutical Design FTY720 (Fingolimod) Ameliorates Brain Injury through Multiple Mechanisms and is a Strong Candidate for Stroke Treatment
Current Medicinal Chemistry Cardiovascular Disease and Inflammation: Novel Biomarkers of Inflammation and Endothelial Activation
Vascular Disease Prevention (Discontinued)